You are leaving the Blue Earth Therapeutics website. By clicking this link, you will be taken to a website that is independent from Blue Earth Therapeutics. The site you are linking to is not controlled or endorsed by Blue Earth Therapeutics and Blue Earth Therapeutics is not responsible for the content provided on that site.

ACCEPT
CANCEL
Contact us
Contact us

    This page is intended for Healthcare Professionals only. Are you a Healthcare Professional?

    Yes No

    More bang for your becquerel:
    Improving the therapeutic index with novel radiopharmaceuticals

    Modelling absorbed doses to tumors and at-risk organs from a novel PSMA-targeted radioligand labeled with Actinium-225 

    2025 SNMMI mid-winter meeting

    Evaluation of a synergistic drug combination with 177Lu-rhPSMA-10.1 for prostate cancer: Results of an in vitro screen and an in vivo proof of concept study

    2024 AACR Meeting

    Preclinical evaluation of 225Ac-rhPSMA-10.1, a novel radiohybrid PSMA compound for targeted alpha therapy of prostate cancer

    2023 EANM Meeting

    Enhanced therapeutic response to 177Lu-rhPSMA-10.1 in pre-clinical models of prostate cancer

    2023 SNMMI Meeting

    Preclinical evaluation of a novel radioligand therapy for patients with prostate cancer: biodistribution and efficacy of 177Lu-rhPSMA-10.1 in comparison with 177Lu-PSMA-I&T

    2022 SNMMI Meeting

    UKBET-rh-2500015 / May 2025